https://www.selleckchem.com/products/byl719.html
To date there has not been an extensive analysis of the outcomes of biomarker use in oncology. Data were pooled across four indications in oncology drawing upon trial outcomes from www.clinicaltrials.gov breast cancer, non-small cell lung cancer (NSCLC), melanoma and colorectal cancer from 1998 to 2017. We compared the likelihood drugs would progress through the stages of clinical trial testing to approval based on biomarker status. This was done with multi-state Markov models, tools that describe the stochastic process in which subjects
Like
Comment
Share
